Table 1 Basic characteristics of included studies in this meta-analysis
Study | Year | Country | Sample size | Gender (M/F) | Age (years) Median(range) | Study period | Study design | TNM stage | Histology | Treatment | SIRI cut-off value | Cut-off determination | Survival outcomes | Survival analysis | Follow-up (months) Median(range) | NOS score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Geng, Y | 2018 | China | 916 | 696/220 | ≤ 60y: 455 > 60y: 461 | 2002–2012 | Retrospective | I-III | ESCC | Surgery | 1.2 | ROC curve | OS | Multivariate | 1–150 | 8 |
Xu, X | 2022 | China | 370 | 245/125 | 61(40–81) | 2016–2018 | Retrospective | I-IV | ESCC | Surgery | 0.485 | ROC curve | OS | Multivariate | 1–60 | 8 |
Yan, K | 2022 | China | 192 | 111/81 | 73(65–88) | 2013–2016 | Retrospective | II-III | ESCC | Radiotherapy | 1.03 | ROC curve | OS, PFS | Multivariate | 21.3(3.8–95.1) | 8 |
Kong, L. Y | 2023 | China | 139 | 125/14 | < 65y: 86 ≥ 65y: 53 | 2015–2018 | Retrospective | I-IV | ESCC | Surgery | 1.39 | ROC curve | OS | Univariate | 1–40 | 7 |
Qi, W. X | 2023 | China | 51 | 44/7 | 62(39–75) | 2019–2022 | Prospective | II-IV | ESCC | CRT + ICIs | 0.94 | ROC curve | PFS | Multivariate | 1–45 | 9 |
Wang, H. K | 2023 | China | 508 | 340/168 | < 65y: 283 ≥ 65y: 225 | 2013–2019 | Retrospective | I-IV | ESCC | Surgery | 0.901 | ROC curve | OS | Multivariate | 1–96 | 8 |